The DOI matches its Crossref record; 75 of the 76 references it cites were found in a registry or an index.
PRIMA-1 and PRIMA-1Met (APR-246): From Mutant/Wild Type p53 Reactivation to Unexpected Mechanisms Underlying Their Potent Anti-Tumor Effect in Combinatorial Therapies
Open accessAbstract
p53 protects cells from genetic assaults by triggering cell-cycle arrest and apoptosis. Inactivation of p53 pathway is found in the vast majority of human cancers often due to somatic missense mutations in TP53 or to an excessive degradation of the protein. Accordingly, reactivation of p53 appears as a quite promising pharmacological approach and, effectively, several attempts have been made in that sense. The most widely investigated compounds for this purpose are PRIMA-1 (p53 reactivation and induction of massive apoptosis )and PRIMA-1Met (APR-246), that are at an advanced stage of development, with several clinical trials in progress. Based on publications referenced in PubMed since 2002, here we review the reported effects of these compounds on cancer cells, with a specific focus on their ability of p53 reactivation, an overview of their unexpected anti-cancer effects, and a presentation of the investigated drug combinations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The most apparent sensitization effect was observed with APR-246 (PRIMA-1Met/Eprenetapopt) (14)(15)(16)(17)(18).”
From Ovarian cancers with low CIP2A tumor expression constitute an APR-246 sensitive disease subtype (2021) · cites this paper as [16]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The most apparent sensitization effect was observed with APR-246 (PRIMA-1Met/Eprenetapopt) (15,19–22). Whereas HEY-CTLshRNA cells were practically insensitive to APR-246, HEY-CIP2AshRNA cells showed a >50% reduction in cell viability (Fig. 1A).”
From Ovarian Cancers with Low CIP2A Tumor Expression Constitute an APR-246–Sensitive Disease Subtype (2022) · cites this paper as [20]
The cited source says what the claim attributes to it.
In the citing paper
“Current data indicate that APR-246 kills cancer cells via multiple mechanisms (20,21,24–26).”
From Ovarian Cancers with Low CIP2A Tumor Expression Constitute an APR-246–Sensitive Disease Subtype (2022) · cites this paper as [20]
The cited source says what the claim attributes to it.
In the citing paper
“On the other hand, several recent studies (using some of the same OvCa cells as here) have shown that APR-246 kills cancer cells independently of TP53, but via induction of reactive oxygen species (ROS) (16,21,22).”
From Ovarian cancers with low CIP2A tumor expression constitute an APR-246 sensitive disease subtype (2021) · cites this paper as [16]
The cited source says what the claim attributes to it.
In the citing paper
“Current data indicate that APR-246 kills cancer cells via multiple mechanisms (16, 17, 20-22).”
From Ovarian cancers with low CIP2A tumor expression constitute an APR-246 sensitive disease subtype (2021) · cites this paper as [16]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mutant p53 in Cancer: New Functions and Therapeutic Opportunities
Muller, P. A. J., & Vousden, K. H. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.01.021 · Cited by 1,545 · cited 2×
“In addition, such mutations push cancer cells to acquire new properties, promoting invasion, migration, angiogenesis, proliferation, genomic instability, or drug resistance [2].”
BackgroundRestoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound
Bykov, V. J. N., Issaeva, N., Shilov, A., Hultcrantz, M., Pugacheva, E., Chumakov, P., Bergman, J., Wiman, K. G., & Selivanova, G. (2002) · Nature Medicine · doi:10.1038/nm0302-282 · Cited by 1,067 · cited 10×
“The main reported mechanism to explain the PRIMA-1/APR-246 induced cell death was the induction of apoptosis, evaluated using common methods such DNA fragmentation [8,28,50,65], morphologic modifications [35,52,68], APO2.”
BackgroundMethodInfluentialBouaoun, L., Sonkin, D., Ardin, M., Hollstein, M., Byrnes, G., Zavadil, J., & Olivier, M. (2016) · Human Mutation · doi:10.1002/humu.23035 · Cited by 730 · cited 1×
“Indeed, somatically, TP53 is the most frequently mutated gene in human cancer overall [1].”
BackgroundPRIMA-1 reactivates mutant p53 by covalent binding to the core domain
Lambert, J. M. R., Gorzov, P., Veprintsev, D. B., Söderqvist, M., Segerbäck, D., Bergman, J., Fersht, A. R., Hainaut, P., Wiman, K. G., & Bykov, V. J. N. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.03.003 · Cited by 592 · cited 11×
“In addition, the anti-tumor effects of PRIMA-1 and APR-246 appeared mediated by changes in cell cycle progression, with an accumulation of cells in the G0/G1 phase [19,24,27,46,48–50,54,60], or in the G2 phase [8,20,26,32,48].”
BackgroundMethodInfluentialLehmann, S., Bykov, V. J. N., Ali, D., Andrén, O., Cherif, H., Tidefelt, U., Uggla, B., Yachnin, J., Juliusson, G., Moshfegh, A., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.40.7783 · Cited by 406 · cited 1×
“The first-in-human study (NCT00900614) that demonstrates, clinically, a good tolerance to the drug and a favorable pharmacokinetic profile, and biologically, an increased apoptosis with upregulation of p53 target genes, concludes to the safety of APR-246 use in hematologic malignancies and prostate cancer [75].”
BackgroundTargeted rescue of a destabilized mutant of p53 by an in silico screened drug
Boeckler, F. M., Joerger, A. C., Jaggi, G., Rutherford, T. J., Veprintsev, D. B., & Fersht, A. R. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0805326105 · Cited by 387 · cited 1×
“, 2008 [6] focused their studies on a specific hot mutation in p53 (Y220C) and they designed Y220C-targeting compounds based on in silico analysis of the crystal structure of the p53 core domain including PK083 and PK7088.”
BackgroundInhibiting the system xC−/glutathione axis selectively targets cancers with mutant-p53 accumulation
Liu, D. S., Duong, C. P., Haupt, S., Montgomery, K. G., House, C. M., Azar, W. J., Pearson, H. B., Fisher, O. M., Read, M., Guerra, G. R., et al. (2017) · Nature Communications · doi:10.1038/ncomms14844 · Cited by 321 · cited 16×
“To confirm the essential role of caspases in PRIMA-1/APR-246 induced cell death, caspase inhibitors have been used, with a reduction, or in some cases, a suppression of the induced apoptosis [10,14,29,36,62,65].”
BackgroundMethodInfluentialPharmacologic activation of p53 elicits Bax-dependent apoptosis in the absence of transcription
Chipuk, J. E., Maurer, U., Green, D. R., & Schuler, M. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00272-1 · Cited by 299 · cited 7×
“The mitochondrial release of cytochrome C [10,14,68] or the activation of caspase-9 [32,43,68] attested to the possible implication of the intrinsic mitochondrial apoptosis, which could be independent of the p53-transcriptional activity [10,22].”
BackgroundInfluentialPRIMA-1MET synergizes with cisplatin to induce tumor cell apoptosis
Bykov, V. J. N., Zache, N., Stridh, H., Westman, J., Bergman, J., Selivanova, G., & Wiman, K. G. (2005) · Oncogene · doi:10.1038/sj.onc.1208419 · Cited by 252 · cited 9×
“The main reported mechanism to explain the PRIMA-1/APR-246 induced cell death was the induction of apoptosis, evaluated using common methods such DNA fragmentation [8,28,50,65], morphologic modifications [35,52,68], APO2.”
BackgroundMethodInfluentialComputational identification of a transiently open L1/S3 pocket for reactivation of mutant p53
Wassman, C. D., Baronio, R., Demir, Ö., Wallentine, B. D., Chen, C.-K., Hall, L. V., Salehi, F., Lin, D.-W., Chung, B. P., Wesley Hatfield, G., et al. (2013) · Nature Communications · doi:10.1038/ncomms2361 · Cited by 223 · cited 1×
“In particular, a pocket between loop L1 and sheet S3 of the p53 core domain, involving the Cys124 residue located at the center of the pocket, has been identified as a possible target of PRIMA-1 [70].”
Background
Research works printed but not linked: 1
- Bykov, 2002, Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound, Nat. Med., 8, 282, 10.1038/nm0302-282 · DOI · Paper page
Cited by
Fucikova, J., Spisek, R., Kroemer, G., & Galluzzi, L. (2021) · Cell Research · doi:10.1038/s41422-020-0383-9 · Cited by 400
Targeting p53 for the treatment of cancer
Duffy, M. J., Synnott, N. C., O’Grady, S., & Crown, J. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.07.005 · Cited by 349
Targeting signaling pathways in prostate cancer: mechanisms and clinical trials
He, Y., Xu, W., Xiao, Y.-T., Huang, H., Gu, D., & Ren, S. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01042-7 · Cited by 261
Mutant p53 in Cancer Progression and Targeted Therapies
Zhu, G., Pan, C., Bei, J.-X., Li, B., Liang, C., Xu, Y., & Fu, X. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.595187 · Cited by 218
APR-246 induces early cell death by ferroptosis in acute myeloid leukemia
Birsen, R., Larrue, C., Decroocq, J., Johnson, N., Guiraud, N., Gotanegre, M., Cantero-Aguilar, L., Grignano, E., Huynh, T., Fontenay, M., et al. (2021) · Haematologica · doi:10.3324/haematol.2020.259531 · Cited by 182
“Altogether, these results demonstrate that APR-246 induces GSH depletion which induces ferroptosis in AML cells irrespective of their TP53 mutational status, and that ferroptosis induction is the main mechanism of cell death after early exposure to APR-246.”
BackgroundInfluential
Metadata
- Authors
- Perdrix, A., Najem, A., Saussez, S., Awada, A., Journe, F., Ghanem, G., & Krayem, M.
- Affiliations
- Université Libre de Bruxelles (BE)
- University of Mons (BE)
- Corresponding author
- Krayem, Mohammad
- Venue
- Cancers
- Publisher
- MDPI AG
- Published
- 2017-12-16
- Volume
- 9
- Issue
- 12
- Pages
- 172
- ISSN
- 2072-6694 (ISSN-L)
- PMC
- PMC5742820
- OpenAlex
- W2776139938
- Cited by
- 126
- References
- 76
- Citations by year
- 2026: 3 · 2025: 14 · 2024: 14 · 2023: 18 · 2022: 22 · 2021: 20 · 2020: 13 · 2019: 17 · 2018: 4
- FWCI
- 0.98
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Cancers (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- ORBi UMONS (submittedVersion, other-oa)
- HAL (submittedVersion)
- Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles) (submittedVersion, other-oa)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Keywords
- PRIMA-1, APR-246, p53 reactivation, TP53 mutation, p53 degradation, p53-targeted therapy, anticancer mechanism, combination therapy, apoptosis, cancer therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: PRIMA-1 and PRIMA-1Met (APR-246): From Mutant/Wild Type p53 Reactivation to Unexpected Mechanisms Underlying Their Potent Anti-Tumor Effect in Combinatorial Therapies. https://app.cochat.ai/papers/10.3390/cancers9120172
- The paper
- Perdrix, A., Najem, A., Saussez, S., Awada, A., Journe, F., Ghanem, G., & Krayem, M. (2017). PRIMA-1 and PRIMA-1Met (APR-246): From Mutant/Wild Type p53 Reactivation to Unexpected Mechanisms Underlying Their Potent Anti-Tumor Effect in Combinatorial Therapies. Cancers. https://doi.org/10.3390/cancers9120172
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
